Search | Clinical Trials Finder

Conditions: Headache, Migraine, Tension Headache, Occipital Neuralgia
Interventions: 0.5% Bupivacaine HCl, standard IV treatment for headache; Drug
Lead sponsor: HCA Florida North Florida Hospital; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Uncomplicated Urinary Tract Infections
Interventions: Pivya (Pivmecillinam 185 mg), Nitrofurantoin 100 mg (nitrofurantoin monohydrate/macrocrystalline capsule); Drug
Lead sponsor: Alembic Therapeutics; Industry
Eligibility: 12 Years to 17 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Dearborn Heights, Michigan

Conditions: Schizophrenia
Interventions: Placebo, Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 765 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 25
States / cities: Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 20 more

Conditions: Pulmonary Hypertension
Interventions: UT-15C 1 mg, UT-15C 0.25 mg, UT-15C 5 mg, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more

Conditions: Bleeding
Interventions: TachoSil®, Surgicel® Original; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 37
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 25 more

Conditions: Hepatic Impairment
Interventions: Molnupiravir; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Hollywood, Florida • Miami, Florida • Philadelphia, Pennsylvania

Conditions: Endometriosis
Interventions: Elagolix, Placebo, Combined Oral Contraceptive; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 176
States / cities: Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 134 more

Conditions: Type 1 Diabetes Mellitus
Interventions: SAR342434, insulin lispro; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 19 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Little Rock, Arkansas • Denver, Colorado

Conditions: Hepatic Impairment
Interventions: BMS-986263; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Fat-free Masss, Muscle Strength, Neuromuscular Function
Interventions: Fish oil, Coconut oil; Dietary Supplement
Lead sponsor: Rowan University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Glassboro, New Jersey

Conditions: Diabetic Retinopathy
Interventions: BI 765128, Sham comparator; Drug · Other
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 11
States / cities: Bakersfield, California • Sacramento, California • Walnut Creek, California + 7 more

Conditions: Kidney Transplantation in Highly Sensitized Patients
Interventions: Imlifidase, PLEX, IVIg, Anti-CD20 antibodies, Eculizumab, Remain on wait list; Drug · Procedure · Other
Lead sponsor: Hansa Biopharma AB; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more

Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions: Remternetug, Matching Placebo (Remternetug); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2034
U.S. locations: 13
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more

Conditions: Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV)
Interventions: Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support; Drug · Behavioral
Lead sponsor: Nicky Mehtani, MD, MPH; Other
Eligibility: 25 Years to 64 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non Cystic Fibrosis Bronchiectasis
Interventions: Ciprofloxacin dispersion for inhalation, Placebo; Drug
Lead sponsor: Aradigm Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 30
States / cities: Peoria, Arizona • Phoenix, Arizona • Downey, California + 27 more

Conditions: Preterm Birth
Interventions: Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo; Drug · Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio

Conditions: Idiopathic Hypersomnia
Interventions: JZP-258, Placebo Oral Solution; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 40
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: BIIB147, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 2
States / cities: St Louis, Missouri • Austin, Texas

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Non-adaptive Floreo VR control, Floreo Virtual Reality application; Behavioral
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 8 Years to 16 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis
Interventions: Placebo, M2951; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Billerica, Massachusetts

Conditions: Healthy, Hepatic Impairment
Interventions: Selpercatinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Anaheim, California • Monterey Park, California • Tustin, California + 4 more

Conditions: Epilepsy, Focal Seizures, Partial Seizures
Interventions: Natalizumab, Placebo; Drug · Other
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 26 more

Conditions: PCDH19-Related Epilepsy
Interventions: Ganaxolone, Placebo; Drug
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 1 Year to 17 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 3 more

Conditions: Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
Interventions: branebrutinib, abatacept, branebrutinib placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 40
States / cities: Phoenix, Arizona • Covina, California • Encino, California + 35 more

Search by objective public record fields.

0.5% Bupivacaine Lower Cervical Intramuscular Injection vs IV Medications for Headache Treatment

A Study to Investigate Pivmecillinam Versus Nitrofurantoin in Female Adolescents 12 to Less Than 18 Years of Age With Uncomplicated Urinary Tract Infection

A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery

A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)

Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion

A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment

Effects of Fish Oil and Resistance Training on Muscle Mass and Function

A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment

Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Psilocybin Therapy for Methamphetamine Use Disorder and HIV

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)

Assessment of DHA On Reducing Early Preterm Birth

A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension

A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS)

Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial

Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis

A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis